KR20230059929A - Composition of dog food for weight control using citrus meal, whey and lactic acid bacteria dead cells bioconversion - Google Patents

Abstract

The present invention relates to a feed composition of companion dogs for weight control containing citrus peel, whey, and lactic acid bacteria bioconversion and dead lactic acid bacteria cells. The feed composition of companion dogs for weight control comprises a citrus peel extract, whey, and lactic acid bacteria as active ingredients. According to the present invention, the body weight, weight gain, and fat tissue weight of companion dogs can be reduced, and neutral lipids can be lowered.

Description

Composition of dog food for weight control using citrus meal, whey and lactic acid bacteria dead cells bioconversion

The present invention provides a dog food composition for weight control using citrus peel, whey, and dead cell bioconversion of lactic acid bacteria.

Bio Conversion or Bio Transformation is a technique in which dispersions derived from plants or animals are transformed into useful metabolites by transforming their chemical structures by the action of microorganisms, and are actively applied to food, medicine, agriculture, etc. Bio-conversion using lactic acid bacteria with enzymatic activity such as β-glucosidase is used to change the chemical structure of polyphenols such as hesperidin and naringin, which are abundant in citrus fruits, into aglycones to reduce bitterness. While reducing, there is an advantage of maintaining the physiological activity as it is.

Citrus peel can be an excellent feed resource in terms of composition and palatability, so it is used as a simple feed. In particular, tangerine peel contains a large amount of pectin, vitamin C, carotenoids, etc., and is known to be highly useful as a source of immunity enhancement and antioxidant material. there is. However, considering the excellent nutritional and economic benefits of citrus peels and aspects such as environmental preservation and maintenance of the local economy, tangerine peels are expected to have unlimited potential for development as pet food.

Whey is a by-product obtained during the cheese manufacturing process. Its main components are proteins and lactose, excluding casein. It contains vitamins, minerals, and essential amino acids (branched chain amino acids and It contains tryptophan), lactic acid and enzymes, so it is used as a food and drug ingredient for various sports nutrition products using whey, prevention of colorectal cancer, immunity enhancement, and weight control.

The yield of cheese is 10%, and if cheese is produced with 100L of milk, about 90L of whey can be obtained. Production is increasing along with the increase in cheese consumption by about 10 times of the cheese consumption.

Through bioconversion using whey, lactic acid bacteria not only produce various useful physiologically active substances, but also the activity of β-galactosidase of lactic acid bacteria produces oligosaccharides, etc. can exert

The market related to lactic acid bacteria probiotics, which is expected to increase at an average annual rate of 11.3% from 2019 to 2023, along with the growth of the global market related to the intestinal microbiome, a product using lactic acid bacteria (from $ 81.1 billion in 2019 to $ 108.7 billion in 2023), is expected to grow in the future. It has sales potential, and the demand for feed with functional substances added is increasing due to the increase in obese animals due to lack of exercise of companion animals due to indoor breeding, and about 40% or more of companion animals are overweight or obese. The phenomenon is defined by the North American Veterinary Community (NAVC) in 2019 as an "epidemic" in the United States.

Obesity in companion animals is closely related to serious diseases such as endocrine system, metabolic syndrome, heart disease, joint disease, and decreased immune function. There is an urgent need to develop customized feeds according to the increase in feed consumption.

The companion animal-related market shows a rapid growth rate of more than double digits every year, and it is urgent to develop technology using domestic materials that can secure competitiveness in the domestic companion animal food industry, where imported feed accounts for 70% (by value).

Therefore, the present inventors found that the anti-obesity was maximized by reducing the bitterness of the citrus peel extract by lactic acid bacteria, promoting the growth of lactic acid bacteria by oligosaccharides synthesized from cheese whey and citrus peel extract polyphenols, and containing useful physiologically active substances and anti-obesity lactic acid bacteria. Companion animal feed materials were developed.

(KR)10-2037108

1. Tesfaw, A., Oner, E. T., & Assefa, F. (2021) "Evaluating crude whey for bioethanol production using non-Saccharomyces yeast, Kluyveromyces marxianus" SN Applied Sciences, 3(1), 1-8. 2. Ariyanti, D., & Hadiyanto, H. (2013). "Ethanol Production from Whey by Kluyveromyces marxianus in Batch Fermentation System: Kinetics Parameters Estimation" Bulletin of Chemical Reaction Engineering & Catalysis, 7(3), 179. 3. Berwig, K. H., Baldasso, C., & Dettmer, A. (2016). "Production and characterization of poly(3-hydroxybutyrate) generated by Alcaligenes latus using lactose and whey after acid protein precipitation process" Bioresource technology, 218, 31-37.

An object of the present invention is to provide a feed composition for weight control comprising citrus peel extract, whey and lactic acid bacteria as active ingredients.

An object of the present invention is to provide a feed composition for preventing and improving obesity, comprising citrus peel extract, whey, and lactic acid bacteria as active ingredients.

An object of the present invention is to provide a food composition for preventing and alleviating obesity, comprising citrus peel extract, whey, and lactic acid bacteria as active ingredients.

An object of the present invention is to provide a pharmaceutical composition for the prevention and treatment of obesity containing citrus peel extract, whey and lactic acid bacteria as active ingredients.

The present invention provides a feed composition for weight control comprising citrus peel extract, whey and lactic acid bacteria as active ingredients.

The present invention provides a feed composition for preventing and improving obesity, comprising citrus peel extract, whey, and lactic acid bacteria as active ingredients.

The present invention provides a food composition for preventing and improving obesity, comprising citrus peel extract, whey, and lactic acid bacteria as active ingredients.

The present invention provides a pharmaceutical composition for the prevention and treatment of obesity containing citrus peel extract, whey and lactic acid bacteria as active ingredients.

The present invention is a highly functional weight control dog food composition containing citrus peel extract, whey and lactic acid bacteria as active ingredients. decreased, and through blood biochemical analysis, it was confirmed that triglyceride (TG) was lowered. In addition, the metabolic rate and weight of the liver and kidneys were kept constant through dietary intake, and aspartate aminotransferase (AST, alanine aminotransferase), total cholesterol through blood biochemical analysis , (Total Cholesterol), high density lipoprotein cholesterol (HDL-C), heart disease marker (Total Cholesterol (TC, High Density Lipoprotein Cholesterol) ratio), blood sugar ( Glucose), insulin, and insulin resistance measurement (HOMA-IR, Homeostatic Model Assessment for Insulin Resistance) values were also kept constant. Therefore, the composite raw material containing the citrus peel extract, whey, and lactic acid bacteria of the present invention has excellent effects as a highly functional weight control dog food composition, and can be usefully used in related businesses.

1 is a diagram showing a powdered sample of whey, lactic acid bacteria ( Lactobacillus kefiri DH5) and citrus peel, which are the composite raw materials of the present invention.
2 is a diagram showing changes in body weight and weight gain after feeding the composite raw material of the present invention and a control group to a mouse model for 5 weeks.
Figure 3 is a diagram showing the change in metabolic rate after feeding the composite raw material to the mouse model ingesting the diet of the present invention for 5 weeks.
Figure 4 is a diagram showing the change in the weight of the liver, adipose tissue and kidney after feeding the composite raw material of the present invention and a control group to a mouse model for 5 weeks.
5 is a diagram showing the results of AST, ALT, and TG through blood biochemical tests after feeding the composite raw material of the present invention and a control group to a mouse model for 5 weeks.
(Aspartate aminotransferase (AST), alanine aminotransferase (ALT, alanine aminotransferase), neutral lipid, (TG, triglyceride))
Figure 6 is a diagram showing T. Cholesterol and HDL-C through blood biochemical tests after feeding the composite raw material of the present invention and a control group to a mouse model for 5 weeks.
(Total Cholesterol, High Density Lipoprotein Cholesterol (HDL-C))
Figure 7 is a diagram showing the TC / HDL ratio, a heart disease marker, through T. Cholesterol and HDL-C results through blood biochemical tests after feeding the composite raw material of the present invention and a control group to a mouse model for 5 weeks.
8 is a diagram showing the results of blood glucose and insulin through blood biochemical tests after feeding the composite raw material of the present invention and a control group to a mouse model for 5 weeks.
FIG. 9 is a diagram showing the measured insulin resistance value (HOMA-IR) as the resultant values of glucose and insulin in FIG. 8 .

Hereinafter, the present invention will be described in detail as an embodiment of the present invention with reference to the accompanying drawings. However, the following embodiments are presented as examples of the present invention, and if it is determined that detailed descriptions of well-known techniques or configurations may unnecessarily obscure the gist of the present invention, the detailed descriptions may be omitted. , the present invention is not limited thereby. Various modifications and applications of the present invention are possible within the scope of the claims described below and equivalents interpreted therefrom.

The present invention provides a feed composition for weight control comprising citrus peel extract, whey and lactic acid bacteria as active ingredients.

The term "extract" used in the present invention refers to a preparation obtained by extracting citrus peel with an appropriate extraction solvent and evaporating the solvent to concentrate, but is not limited thereto, an extract obtained by extraction treatment, and a diluted solution of the extract. Alternatively, it may be a dried product obtained by drying a concentrated solution or an extract, or a crude or purified product thereof. The citrus peel extract can be prepared using a general extraction method, separation and purification method known in the art. The extraction method is not limited thereto, but preferably, methods such as hot water extraction, hot water extraction, cold needle extraction, reflux cooling extraction, or ultrasonic extraction may be used.

The citrus peel of the feed composition is dried and processed by-products of the peel generated in the citrus processing process, but is not limited thereto.

The citrus peel extract of the feed composition may be extracted with water, alcohol having 1 to 4 carbon atoms, or a mixed solvent thereof, but is not limited thereto.

Whey of the feed composition may be fermented, but is not limited thereto.

The lactic acid bacteria of the feed composition may be at least one selected from Lactobacillus kefiri , Lactococcus lactis subsp. Lactis , and Leuconostoc mesenteroides , but is not limited thereto. Preferably, it may be Lactobacillus kefiri .

The lactic acid bacteria of the feed composition may be dead cells, but is not limited thereto.

The feed composition reduces body weight and weight gain (body weight gain), but is not limited thereto.

The feed composition maintains metabolism, but is not limited thereto.

The feed composition maintains the weight of liver and kidney, and reduces the weight of adipose tissue, but is not limited thereto.

The feed composition maintains aspartate aminotransferase and alanine aminotransferase, and reduces neutral lipids, but is not limited thereto.

The feed composition maintains total cholesterol and high density lipoprotein cholesterol, but is not limited thereto.

The feed composition is to maintain the TC / HDL ratio, which is a heart disease marker, but is not limited thereto.

The feed composition is to maintain blood sugar (Glucose) and insulin (Insulin), but is not limited thereto.

The feed composition maintains the Homeostatic Model Assessment for Insulin Resistance (HOMA-IR), but is not limited thereto.

The feed composition increases the obesity-improving effect of physiologically active ingredients of citrus peel extract, whey, and dead lactic acid bacteria through bioconversion and reduces bitter taste, but is not limited thereto.

The feed composition of the present invention replaces conventional antibiotics and suppresses the growth of harmful food pathogens, improving the health of animals, improving the weight gain and quality of livestock, and increasing milk production and immunity. can The feed composition of the present invention may be prepared in the form of fermented feed, formulated feed, pellet form and silage. The fermented feed can be prepared by fermenting organic matter by adding various microorganisms or enzymes other than the peptide of the present invention, and the formulated feed can be prepared by mixing several types of general feed with the peptide of the present invention. Feed in the form of pellets can be prepared by applying heat and pressure to the formulated feed, etc. in a pellet machine, and silage can be prepared by fermenting green feed with the microorganism according to the present invention. Wet fermented feed collects and transports organic matter such as food waste, mixes excipients for sterilization and moisture control in a certain ratio, and ferments for more than 24 hours at a temperature suitable for fermentation, so that the moisture content is about 70%. It can be made by adjusting. The fermented dry feed can be prepared by further subjecting the wet fermented feed to a drying process to adjust the moisture content to about 30% to 40%.

The feed composition of the present invention may further include components added to conventional feed. Examples of ingredients added to such feeds may include grain powder, meat powder, and pulses. In the above, the grain powder may use at least one selected from rice flour, wheat flour, barley flour, and corn flour. In the above meat powder, at least one selected from chicken, beef, pork, and ostrich meat may be used as a powdered meat powder. In the above, at least one selected from soybeans, kidney beans, peas, and black beans may be used as the pulse.

In the feed composition of the present invention, in addition to grain powder, meat powder, and pulses, which are ingredients added to conventional feeds mentioned above, at least one selected from nutrients and minerals may be added to increase the nutritional properties of the feed, and the feed quality In order to prevent the degradation of antifungal agents, antioxidants, anticoagulants, emulsifiers, and at least one selected from a binder may be included.

The present invention provides a feed composition for preventing and improving obesity, comprising citrus peel extract, whey, and lactic acid bacteria as active ingredients.

The present invention provides a food composition for preventing and improving obesity, comprising citrus peel extract, whey, and lactic acid bacteria as active ingredients.

In addition to containing the active ingredient, the food composition of the present invention may contain various flavoring agents or natural carbohydrates as additional ingredients like conventional food compositions.

Examples of the aforementioned natural carbohydrates include monosaccharides such as glucose, fructose, and the like; disaccharides such as maltose, sucrose and the like; and polysaccharides such as conventional sugars such as dextrins and cyclodextrins, and sugar alcohols such as xylitol, sorbitol and erythritol. As the flavoring agents described above, natural flavoring agents (thaumatin), stevia extracts (eg rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.) can advantageously be used. The food composition of the present invention can be formulated in the same way as the pharmaceutical composition and used as a functional food or added to various foods. Foods to which the composition of the present invention can be added include, for example, beverages, meat, chocolate, foods, confectionery, pizza, ramen, other noodles, gum, candy, ice cream, alcoholic beverages, vitamin complexes and health supplements, etc. there is

In addition, the food composition, in addition to the active ingredient extract, various nutrients, vitamins, minerals (electrolytes), flavors such as synthetic flavors and natural flavors, colorants and enhancers (cheese, chocolate, etc.), pectic acid and its salts, Alginic acid and its salts, organic acids, protective colloidal thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohol, carbonating agents used in carbonated beverages, and the like may be contained. In addition, the food composition of the present invention may contain fruit flesh for preparing natural fruit juice, fruit juice beverages, and vegetable beverages.

The functional food composition of the present invention may be prepared and processed in the form of tablets, capsules, powders, granules, liquids, pills, and the like. In the present invention, 'health functional food composition' refers to a food manufactured and processed using raw materials or ingredients having useful functionality for the human body according to Health Functional Food Act No. 6727, and the structure and function of the human body It refers to intake for the purpose of obtaining useful effects for health purposes such as regulating nutrients or physiological functions. The health functional food of the present invention may contain ordinary food additives, and the suitability as a food additive is determined according to the general rules of the Food Additive Code and General Test Methods approved by the Food and Drug Administration, unless otherwise specified. It is judged according to standards and standards. Examples of the items listed in the 'Food Additive Code' include, for example, chemical compounds such as ketones, glycine, calcium citrate, nicotinic acid, and cinnamic acid; natural additives such as persimmon pigment, licorice extract, crystalline cellulose, kaoliang pigment, and guar gum; and mixed preparations such as sodium L-glutamate preparations, noodle-added alkali preparations, preservative preparations, and tar color preparations. For example, a health functional food in the form of a tablet is obtained by granulating a mixture obtained by mixing the active ingredient of the present invention with an excipient, a binder, a disintegrant, and other additives in a conventional manner, and then adding a lubricant or the like to compression molding, or as described above. The mixture can be directly compression molded. In addition, the health functional food in the form of a tablet may contain a flavoring agent and the like as needed. Among health functional foods in the form of capsules, hard capsules can be prepared by filling a mixture in which the active ingredient of the present invention is mixed with additives such as excipients in a normal hard capsule. It can be prepared by filling the mixture mixed with gelatin in a capsule base. The soft capsule may contain a plasticizer such as glycerin or sorbitol, a colorant, a preservative, and the like, if necessary. The health functional food in the form of a pill can be prepared by molding a mixture of the active ingredient of the present invention mixed with an excipient, a binder, a disintegrant, etc. by a conventionally known method, and can be coated with sucrose or other coating agent if necessary, Alternatively, the surface may be coated with a material such as starch or talc. Health functional food in the form of granules can be prepared in granular form by a conventionally known method of mixing the active ingredient of the present invention with excipients, binders, disintegrants, etc., and, if necessary, flavoring agents, flavoring agents, etc. can

The present invention provides a pharmaceutical composition for the prevention and treatment of obesity containing citrus peel extract, whey and lactic acid bacteria as active ingredients.

The pharmaceutical composition of the present invention may further include an adjuvant in addition to the active ingredient. As long as the adjuvant is known in the art, any one may be used without limitation, but, for example, Freund's complete adjuvant or incomplete adjuvant may be further included to increase immunity.

The pharmaceutical composition according to the present invention may be prepared in the form of incorporating the active ingredient into a pharmaceutically acceptable carrier. Here, the pharmaceutically acceptable carrier includes carriers, excipients and diluents commonly used in the pharmaceutical field. Pharmaceutically acceptable carriers usable in the pharmaceutical composition of the present invention include, but are not limited to, lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum acacia, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.

The pharmaceutical composition of the present invention may be formulated and used in the form of oral formulations such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, external preparations, suppositories or sterile injection solutions according to conventional methods, respectively. .

When formulated, it may be prepared using diluents or excipients such as commonly used fillers, extenders, binders, wetting agents, disintegrants, and surfactants. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc., and such solid preparations contain at least one or more excipients such as starch, calcium carbonate, sucrose, lactose, and gelatin in addition to active ingredients. It can be prepared by mixing etc. In addition to simple excipients, lubricants such as magnesium stearate and talc may also be used. Liquid preparations for oral administration include suspensions, solutions for oral administration, emulsions, syrups, etc. In addition to commonly used diluents such as water and liquid paraffin, various excipients such as wetting agents, sweeteners, aromatics, and preservatives may be included. can Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized formulations and suppositories. Propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate may be used as non-aqueous solvents and suspending agents. As a base material for suppositories, witepsol, tween 61, cacao paper, laurin paper, glycerogelatin, and the like may be used.

The pharmaceutical composition according to the present invention can be administered to a subject by various routes. All modes of administration are contemplated, eg oral, intravenous, intramuscular, subcutaneous, intraperitoneal injection.

The pharmaceutical composition may be formulated into various oral or parenteral dosage forms.

Formulations for oral administration include, for example, tablets, pills, hard and soft capsules, solutions, suspensions, emulsifiers, syrups, granules, etc. chlorose, mannitol, sorbitol, cellulose and/or glycine), lubricants such as silica, talc, stearic acid and magnesium or calcium salts thereof and/or polyethylene glycol. In addition, the tablet may contain a binder such as magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose and/or polyvinylpyrrolidine, and in some cases, starch, agar, alginic acid or a disintegrant or effervescent mixture, such as its sodium salt, and/or absorbents, colorants, flavors, and sweeteners. The formulation may be prepared by conventional mixing, granulating or coating methods.

Representative formulations for parenteral administration are formulations for injection, and water, Ringer's solution, isotonic physiological saline or suspension may be used as a solvent for the formulation for injection. Sterile fixed oils of the above injectable preparations may be used as a solvent or suspension medium, and any bland fixed oil may be used for this purpose, including mono- and di-glycerides. The formulation for injection may use a fatty acid such as oleic acid.

So far, the present invention has been looked at with respect to its preferred embodiments. Those skilled in the art to which the present invention pertains will be able to understand that the present invention can be implemented in a modified form without departing from the essential characteristics of the present invention. Therefore, the disclosed embodiments should be considered from an illustrative rather than a limiting point of view. The scope of the present invention is shown in the claims rather than the foregoing description, and all differences within the equivalent scope will be construed as being included in the present invention.

[Example]

Example 1. Functional composite raw material sample preparation

Citrus Peel Extract, Whey and Lactic Acid Bacteria Culture Conditions and Optimal Manufacturing Conditions for Bioconvision Functional Complex Ingredients

(1) Establishment of manufacturing conditions for citrus peel extract.

The peel of a citrus variety ( Citrus unshiu ) The citrus peel was dried in a dry oven at 80 ° C for 48 hours, then pulverized to 75 mesh, and the pulverized citrus peel powder was stirred in 80% ethanol for one day at room temperature, filtered (Whatman No. 1), and then concentrated under reduced pressure at 40 ° C. After freeze-drying (yield: 28.5%).

(2) Anti-obesity lactic acid bacteria culture conditions

The lactic acid strain used in the present invention is a kefir-derived lactic acid strain that showed anti-obesity efficacy in a previous study by the present research team and was isolated from kefir, a natural complex fermented milk. Briefly, after diluting kefir with sterile physiological saline, it was spread on de Man, Rogosa and Sharpe (MRS) agar, and colonies obtained were identified through 16S rRNA sequencing. For the vitality of the lactic acid strain before the experiment, it was subcultured twice under aerobic conditions at 30 ° C. for 48 hours on MRS agar.

The lactic acid bacterium was named Lactobacillus coffeeary DH5 (accession number: KCCM 118379P) and was used in the present invention.

(3) Whey Manufacturing

Whey produced as a by-product of cheese production was supplied from Farm A in Gyeonggi-do. Whey supplied from Farm A in Gyeonggi-do was sterilized at 80℃ for 10 minutes to remove harmful bacteria. In addition, reducing sugar was measured by dinitrosalicylic acid (DNS) analysis to measure reducing sugar in whey, and reducing sugar in the whey was compared with reducing sugar in general cheese whey with reference to prior art literature, non-patent documents 1 to 3, and the whey of the present invention As shown in Table 1, Cheese whey, which has a higher lactose content than conventional whey, was used.

Determination of reducing sugars using DNS analysis Types of Whey Lactose content (mg/mL) references Cheese whey 30.87 Whey used in current experiment Tigist dariya crude whey 34.4±1.3 Tesfaw, A et al., 2021 Animal dairy crude whey 28.6±1.2 Shola dairy crude whey 27.9±1.2 Cheese whey 45 Ariyanti, D., & Hadiyanto, H, 2013

(4) A method for producing low-concentration and medium-concentration complex ingredients of citrus peel extract, whey and lactic acid bacteria according to the present invention.

① Sterilization of whey

Add 2% yeast extract (10 g based on 500 mL / 6 g based on 300 mL) and 0.5% dextrose (2.5 g based on 500 mL / 1.5 g based on 300 mL) to 500 mL of whey and sterilize at 80 ° C for 10 minutes (sterilization).

② Complex raw material production and mass cultivation

The low- and medium-concentration manufacturing method of the citrus peel extract, whey and lactic acid bacteria complex raw materials of the present invention is as follows.

After streaking the lactobacillus coffeeary DH5 bacteria on the MRS agar plate under conditions of 37 ° C or less, culture for 2 days to activate the primary, and put the primary activated bacteria in 10mL of MRS broth, fill the loop, and incubate for 2 days. Secondary activation. After that, the secondary activated bacteria (10mL) were put into 500mL MRS broth and cultured for 2 days.

The mass-cultured bacteria were divided into 250 mL each in a sterile bottle, centrifuged at 8000 g , 4 ° C, and centrifuged for 10 minutes (10 min centrifuge), discarded the supernatant, washed with 50 mL of saline or PBS, and washed at 8000 g , 4 ° C, 5 minutes was centrifuged (5 min centrifuge).

Then, the supernatant was discarded, washed with 50 mL of saline or PBS, washed twice at 8000 g , 4 ° C, and centrifuged for 5 minutes (5 min centrifuge), and then the previously sterilized whey of ① was added, and the citrus peel extract was After adding 0.5%, 100 μL of 900 μL saline was added, diluted stepwise up to 10 ^-6 , and the number of bacteria was measured by smearing (0 h). After 24 hours (24h), pH and number of bacteria (10 ^-7 to 10 ^-8 ) were measured and sonicated (30 % pulse, on 50 s, off 59 s, total time 150 s).

③ Production of low and medium concentrations of complex raw materials

After completing all of the above steps, if subdivided into 50 mL falcon by 10 mL, the above 5) complex raw material low concentration, if subdivided into 20 mL each, the above 6) complex raw material medium concentration, and when freeze-dried after freezing in a deep freezer, complex raw material low concentration as shown in FIG. , medium concentrations were prepared.

(The mixing ratio of the composite raw material of the present invention is 100:0.5:2 with 0.5g of citrus peel extract and 2mL (2x10^8 cfu) of lactic acid bacteria based on the amount of whey in 100mL.)

(5) Establishment of optimal conditions for bioconversion of citrus peel extract, whey and lactic acid bacteria.

In order to verify the anti-obesity efficacy and safety of functional complex ingredients, whey, anti-obesity lactic acid bacteria ( Lactobacillus kefiri DH5), citrus peel, low-concentration and medium-concentration ingredients of complex ingredients were prepared.

The experiment consisted of 1) control group (administration of sterilized saline, HF+saline), 2) single experimental group (HF+whey), 3) single experimental group (HF+lactic acid bacteria), 4) single experimental group (HF+citrus peel), 5) low-concentration experimental group of complex ingredients ( HF+complex low), 6) Complex raw material medium concentration (HF+complex) Experimental group, a total of 6 groups, were prepared by feeding high-fat diet feed during the experimental period.

Citrus peel extract, whey, and lactic acid bacteria were dried and powdered. In the case of complex raw materials, whey was fermented together with citrus peel extract and lactic acid bacteria at different concentrations to prepare (FIG. 1).

Prior to the animal experiment, in the case of the citrus peel extract and lactic acid bacteria of 2) to 4), the concentration was adjusted to 100 mg per 1 kg of body weight of the animal model, and the concentration of whey was adjusted to 1.8 mg. In addition, the low concentration of the complex raw material of 5) above was adjusted to a concentration of 0.9 mg per 1 kg of the body weight of the animal model, and the medium concentration of the above 6) was adjusted to a concentration of 1.8 mg.

Example 2. Animal model preparation and experiments

In order to confirm the anti-obesity efficacy and safety of functional complex ingredients, animal experiments were conducted after receiving a review (KU21072) from the Animal Experiment Ethics Committee of Konkuk University.

The experiment consisted of 1) control group (administration of sterilized saline, HF+saline), 2) single experimental group (HF+whey), 3) single experimental group (HF+lactic acid bacteria), 4) single experimental group (HF+citrus peel), 5) low-concentration experimental group of complex ingredients ( HF+complex low), 6) Complex raw material medium concentration (HF+complex) Experimental group, a total of 6 groups, were prepared by feeding high-fat diet feed during the experimental period.

In the case of the sample, after adjusting the concentration, it was freeze-dried and stored at -80 ° C. It was prepared by sufficiently dissolving it in sterile saline immediately before oral administration, and orally administered using a sonde at 0.2mL per animal for each group at 16:00 every day. and feed intake were measured. Immediately before autopsy, feces were collected through induction of defecation of 5 animals in each group for metagenome analysis.

Example 3. Changes in body weight and weight gain after feeding composite raw materials to animal models

When the complex raw material of the present invention was fed to an animal model in which obesity was induced, in order to confirm the change in body weight and weight gain by week (5 weeks), according to Example 1 The raw materials of 1) to 6) were fed to a mouse model in which obesity was induced according to Example 2 for 5 weeks.

As a result, the weight change (Table 2) of the mouse model was confirmed for each week, and the change in weight gain (Table 3) was also confirmed for each week. As a result, as shown in FIG. 2, body weight and body weight gain In the 3rd and 4th weeks, compared to the control group, it was confirmed that the low and medium concentration groups of the complex raw materials were significantly less ( p < 0.05).

Changes in body weight through 5-week animal experiments AVG wk0 wk1 wk2 wk3 wk4 HF+saline 18.28 22.50 24.48 26.04 27.18 HF+Whey 18.25 21.96 24.13 25.41 26.81 HF+Lactobacillus 18.26 21.03 22.98 24.47 25.72 HF+Citrus Peel 18.32 21.39 23.35 25.1 26.89 HF+composite low 18.28 20.72 21.26 22.575 23.02 During HF+complex 18.21 18.64 20.35 21.2 21.85

Changes in body weight gain through 5-week animal experiments AVG wk0 wk1 wk2 wk3 wk4 HF+saline 0 4.22 6.2 7.76 8.9 HF+Whey 0 3.71 5.88 7.16 8.56 HF+Lactobacillus 0 2.77 4.72 6.21 7.46 HF+Citrus Peel 0 3.07 5.03 6.78 8.57 HF+composite low 0 2.44 2.98 4.09 4.37 During HF+complex 0 0.77 2.5 3.35 4

Example 4. Changes in daily total energy after feeding animal models of food intake and complex raw materials

When feeding the compound raw material of the present invention at the time of dietary intake to the animal model of which obesity was induced of the present invention, in order to confirm the metabolism, according to Example 1, the raw materials of 1) to 6 were added to the mouse model of which obesity was induced by 5 paid weekly.

As a result, as shown in FIG. 3, there was no significant difference in daily total energy in all experimental groups.

Example 5. Weight change of liver, fat, and kidney after feeding complex raw materials to animal models

When the complex raw material of the present invention was fed to an animal model in which obesity was induced, in order to examine changes in liver, fat, and kidney weights, the raw materials of 1) to 6) according to Example 1 were used in obesity-induced animal models according to Example 2. The induced mouse model was fed for 5 weeks.

As a result, as shown in FIG. 4, there was no significant difference between the control group and the experimental group in the weight of the liver and kidney compared to the weight of the animal model, and the weight of adipose tissue compared to the animal model weight was compared to the control group. It was confirmed that the weight was significantly lowered.

Example 6. Changes in AST, ALT and TG in blood after feeding complex raw materials to animal models

When the complex raw material of the present invention was fed to an animal model in which obesity was induced, aspartate aminotransferase (AST), Alanine aminotransferase (ALT) And in order to examine changes in triglyceride (TG), the raw materials of 1) to 6) according to Example 1 were fed to a mouse model in which obesity was induced according to Example 2 for 5 weeks.

As a result, aspartate aminotransferase (AST) and In the case of alanine aminotransferase (ALT), there was no significant difference between the control group and the experimental group, confirming that the composite raw material of the present invention has no liver toxicity. In addition, in the case of neutral lipid (TG, triglyceride), it was confirmed that the experimental group fed the medium concentration of the complex raw material was significantly lower than the control group.

Example 7. Changes in T. Cholesterol and HDL-C in the blood after feeding complex raw materials to animal models

When the complex raw material of the present invention is fed to an animal model in which obesity is induced, total cholesterol (Total Cholesterol) and cholesterol accumulated in the blood vessel wall are transported to the liver to prevent arteriosclerosis (HDL-C, high density lipoprotein cholesterol) ) and low density lipoprotein (LDL-C, low density lipoprotein cholesterol) In order to examine the change, the raw materials of 1) to 6) according to Example 1 were fed to a mouse model in which obesity was induced according to Example 2 for 5 weeks.

As a result, as shown in FIG. 6, there was no significant difference between the control group and all experimental groups in total cholesterol and high-density cholesterol (HDL-C) through blood biochemical tests ( p > 0.05), but as shown in FIG. 7 Through blood biochemical tests, it was confirmed that there was no significant difference in TC/HDL ratio, a marker of heart disease ( p > 0.05).

Example 8. After feeding complex raw materials to animal models, changes in blood sugar (Glucose) and insulin (Insulin)

When the complex raw material of the present invention was fed to an animal model in which obesity was induced, the raw materials of 1) to 6) according to Example 1 were used according to Example 2 to examine changes in blood glucose and insulin. This induced mouse model was fed for 5 weeks.

As a result, as shown in FIG. 8, there was no significant difference between the control group and all experimental groups in blood glucose and insulin through blood biochemical tests, and the results of glucose and insulin in FIG. 8 As a result of measuring insulin resistance (HOMA-IR, Homeostatic Model Assessment for Insulin Resistance), it was confirmed that there was no significant difference between the control group and all other experimental groups (FIG. 9).

Claims (19)

A feed composition for weight control comprising citrus peel extract, whey and lactic acid bacteria as active ingredients. According to claim 1,
The citrus peel is a feed composition for weight control, characterized in that by drying and processing the peel by-products generated in the citrus processing process. According to claim 1
The citrus peel extract is a feed composition for weight control that is extracted with water, alcohol having 1 to 4 carbon atoms, or a mixed solvent thereof. According to claim 1,
The citrus peel is a feed composition for weight control, characterized in that derived from Onju citrus ( Citrus unshiu ). According to claim 1
The lactic acid bacteria are Lactobacillus kefiri ( Lactobacillus kefiri ), Lactococcus lactis ( Lactococcus lactis subsp. Lactis ) and Leuconox Stock Mesenteroides ( Leuconostoc mesenteroides ) Feed composition for weight control, characterized in that at least one selected from. According to claim 1,
The lactic acid bacteria is a feed composition for weight control, characterized in that dead cells. According to claim 1,
The feed composition is a feed composition for weight control, characterized in that for reducing the weight (body weight) and weight gain (body weight gain). According to claim 1,
The feed composition is a feed composition for weight control, characterized in that for maintaining metabolism. According to claim 1,
The feed composition is a feed composition for weight control, characterized in that to maintain the weight of the liver and kidneys, and to reduce the weight of adipose tissue. According to claim 1,
The feed composition is a feed composition for weight control, characterized in that maintaining the aspartate aminotransferase (Aspartate aminotransferase) and alanine aminotransferase (Alanine aminotransferase), and reducing neutral lipids. According to claim 1,
The feed composition is a feed composition for weight control, characterized in that for maintaining total cholesterol (Total Cholesterol) and high density lipoprotein cholesterol (High density lipoprotein cholesterol). According to claim 1,
The feed composition is a feed composition for weight control, characterized in that to maintain the TC / HDL ratio, which is a heart disease marker. According to claim 1,
The feed composition is a feed composition for weight control, characterized in that to maintain blood sugar (Glucose) and insulin (Insulin). According to claim 1,
The feed composition is a feed composition for weight control, characterized in that maintaining the insulin resistance measurement (HOMA-IR, Homeostatic Model Assessment for Insulin Resistance). According to claim 1,
The feed composition is a feed composition for weight control, characterized in that the feed target is a companion animal. According to claim 1,
Feed composition for weight control, characterized in that the mixing ratio of the feed composition is 100: 0.5: 2. A feed composition for preventing and improving obesity, comprising citrus peel extract, whey, and lactic acid bacteria as active ingredients. A food composition for preventing and improving obesity, comprising citrus peel extract, whey, and lactic acid bacteria as active ingredients. A composition for preventing and treating obesity comprising citrus peel extract, whey and lactic acid bacteria as active ingredients.

Images